Twist Bioscience Corp (TWST) concluded trading on Thursday at a closing price of $38.17, with 0.45 million shares of worth about $17.0 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -19.18% during that period and on July 03, 2025 the price saw a gain of about 1.30%. Currently the company’s common shares owned by public are about 59.86M shares, out of which, 56.69M shares are available for trading.
Stock saw a price change of 3.33% in past 5 days and over the past one month there was a price change of 23.61%. Year-to-date (YTD), TWST shares are showing a performance of -21.99% which decreased to -17.86% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $27.12 but also hit the highest price of $60.90 during that period. The average intraday trading volume for Twist Bioscience Corp shares is 1.23 million. The stock is currently trading 8.76% above its 20-day simple moving average (SMA20), while that difference is up 12.94% for SMA50 and it goes to -8.70% lower than SMA200.
Twist Bioscience Corp (NASDAQ: TWST) currently have 59.86M outstanding shares and institutions hold larger chunk of about 110.05% of that.
The stock has a current market capitalization of $2.29B and its 3Y-monthly beta is at 2.37. It has posted earnings per share of -$3.26 in the same period. It has Quick Ratio of 4.24 while making debt-to-equity ratio of 0.18. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TWST, volatility over the week remained 5.06% while standing at 5.54% over the month.
Stock’s fiscal year EPS is expected to rise by 40.64% while it is estimated to increase by 36.06% in next year. EPS is likely to grow at an annualized rate of 37.99% for next 5-years, compared to annual growth of 1.70% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wolfe Research on December 13, 2024 offering an Outperform rating for the stock and assigned a target price of $60 to it. Coverage by Guggenheim stated Twist Bioscience Corp (TWST) stock as a Buy in their note to investors on June 04, 2024, suggesting a price target of $53 for the stock. On January 17, 2024, Goldman Upgrade their recommendations, while on September 27, 2023, Berenberg Initiated their ratings for the stock with a price target of $27. Stock get a Sector outperform rating from Scotiabank on January 05, 2023.
